Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada

Journal of Rheumatology

Volumn 33, Issue 3, 2006, Pages 588-596

  Rahme, Elham ^a,c   Toubouti, Youssef ^a   Lelorier, Jacques ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Anti ulcer agents; Cost analysis; Cyclooxygenase 2 inhibitors; Nonsteroidal antiinflammatory agents; Prescriptions

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; METFORMIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE; WARFARIN;

ADULT; ARTICLE; BUDGET; CANADA; CONTROLLED STUDY; DRUG COST; DRUG USE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; STOMACH PROTECTION; THROMBOEMBOLISM;

CYCLOOXYGENASE INHIBITORS; DATABASES, FACTUAL; DRUG COSTS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HEALTH RESOURCES; HUMANS; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PROTECTIVE AGENTS; QUEBEC; STOMACH DISEASES;

EID: 33644767870     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of Osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
2. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000;7:4A-16A.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
4. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
5. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40:1345-50.
6. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23S-9S.
7. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
8. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 2000;27:1373-8.
9. Moore RA. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology Oxford 2002;41 Suppl 1:7-15.
10. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
11. Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002;16:231-40.
12. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197-208.
13. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619.
14. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
15. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
16. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6.
17. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
18. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004;4:116-23.
19. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
20. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411-8.
21. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
22. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology Oxford 2003;42 Suppl 3:iii23-iii31.
23. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200.
24. Sebaldt RJ, Petrie A, Goldsmith CH, Marentette M. Appropriateness of NSAID and coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J Manag Care 2004;10:742-50.
25. Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429-38.
26. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
27. Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001;19 Suppl 1:49-58.
28. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283-92.
29. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806.
30. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003;115:715-20.
31. Cox ER, Motheral B, Frisse M, Behm A, Mager D. Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy. Am J Manag Care 2003;9:735-42.
32. Régie de l'assurance maladie Québec. Tableau 1.01: Nombre de personnes inscrites et admissibles au régime d'assurance maladie du Québec selon le sexe, le groupe d'âge et la région sociosanitaire, Québec, 2002. [Internet. Updated 2004 Aug 27; Accessed November 28, 2005] Available from: http://www.ramq.gouv.qc.ca/fr/statistiques/ documents/2002/tab101.pdf.
33. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
34. Régie de l'assurance maladie du Québec. Liste de médicaments: Modification 7-24 novembre 2004. [Internet. Updated 2004 Nov 18. Accessed November 28, 2005]. Available from: http://www.ramq.gouv.qc.ca/fr/ professionnels/listmed/pdf/modification/liste_medicaments.zip
35. Régie de l'assurance maladie Québec. Tableau 5.01: Nombre de prestataires de l'assistance-emploi selon le sexe, le groupe d'âge et la région sociosanitaire de la personne assurée, régime d'assurance médicaments, Québec, 2002. [Internet. Updated 2004 Aug 27; Accessed November 28, 2005]. Available from: http://www.ramq.gouv.qc.ca/fr/ statistiques/documents/2002/tab501.pdf.
36. Régie de l'assurance maladie Québec. Tableau 5.02: Nombre de personnes âgées de 65 ans et plus selon le sexe, le groupe d'âge et la région sociosanitaire de la personne assurée, régime d'assurance médicaments, Québec, 2002. [Internet. Updated 2004 Aug 27; Accessed November 28, 2005]. Available from: http://www.ramq.gouv.qc.ca/fr/statistiques/documents/2002/tab502.pdf
37. Régie de l'assurance maladie Québec. Tableau 5.03: Nombre d'adhérents selon le sexe, le groupe d'âge et la région sociosanitaire de la personne assurée, régime d'assurance médicaments, Québec, 2002. [Internet. Updated 2004 Aug 27; Accessed November 28, 2005]. Available from: http://www.ramq.gouv.qc.ca/fr/ statistiques/documents/2002/tab503.pdf.
38. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
39. International classification of diseases, 9th revision, clinical modification. Vol. 1, 2, 3. 6th ed. ICD9.CM Millenium Edition. Los Angeles: Practice Management Information Corporation (PMIC); 2003.
40. Chan FK, Graham DY. Prevention of non-steroidal antiinflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051-61.
41. Kimmey MB, Lanas A. Appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004;19 Suppl 1:60-5.
42. Doshi JA, Brandt N, Stuart B. The impact of drug coverage on COX-2 inhibitor use in Medicare. Health Aff Millwood 2004;W4 Suppl Web Exclusives:94-105.
43. McLachlin D, Goodz S, Welner S. Understanding the classes: cyclooxygenase-2 inhibitors. Provincial Reimbursement Advisor 2004;7:45-54.
44. Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 2001;23:1061-79.
45. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics 2001;19:1039-49.
46. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol 2004;57:131-41.
47. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
48. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003;48:12-20.